Europe's CHMP gives thumbs up to ExCellThera's blood cancer cell therapy Zemcelpro
Among its positive recommendations this month, Europe’s CHMP has endorsed marketing authorization for ExCellThera’s Zemcelpro. The medicine is a stem cell transplant treatment for adults with blood cancers that require an allogeneic hematopoietic stem cell transplantation after myeloablative conditioning for whom no other type of suitable donor cells is available.
Among its positive recommendations this month, Europe’s CHMP has endorsed marketing authorization for ExCellThera’s Zemcelpro. The medicine is a stem cell transplant treatment for adults with blood cancers that require an allogeneic hematopoietic stem cell transplantation after myeloablative conditioning for whom no other type of suitable donor cells is available.
